Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.

Pharmaceutical

Azura Ophthalmics

Azura Ophthalmics' headquarters in Tel Aviv-Yafo, Israel

��

People (1)

Jobs (0)

Other offices

��������

People (1)

Jobs (0)

Other offices

��